<DOC>
	<DOC>NCT00968695</DOC>
	<brief_summary>Pharmacodynamic study of pathophysiological nature to assess the effects of prolonged administration of human albumin in the cardiocirculatory and renal function and hepatic hemodynamics in patients with advanced cirrhosis and ascites.</brief_summary>
	<brief_title>Clinical Trial on the Effects of Long Term Administration of 20% Albumin in the Cardiovascular and Renal Function, And Hepatic Hemodynamics in Advanced Patients With Cirrhosis and Ascites.</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ascites</mesh_term>
	<criteria>Age above 18 years and less than 80 years. Diagnosis of liver cirrhosis by biopsy or by clinical, laboratory, or ultrasound. Daily requirement of diuretics at least 200mg of spironolactone or 100mg of spironolactone and 40 mg of furosemide Renal dysfunction defined by a plasma concentration of serum creatinine ≥ 1.2 mg / dl, BUN ≥ 25 mg / dl or a serum sodium concentration ≤ 130 mEq / L. Refractory Ascites (paracentesis requirements over 1 month. Neoplastic disease including liver cancer if it exceeds the Milan criteria (one nodule&gt; 5 cm or three nodules&gt; 3 cm). History of transjugular intrahepatic portosystemic shunt (TIPS) or surgical shunt Gastrointestinal bleeding or bacterial infection documented in the past 15 days. Heart failure or structural heart disease. Organic renal insufficiency(proteinuria, hematuria and / or ultrasound data nephropathy). Moderate or severe lung chronic disease. Transplant. Infection with human immunodeficiency virus. Active addiction to drugs. Mental state that prevents the patient understand the nature, extent and consequences of the study, except for hepatic encephalopathy. Pregnancy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>